title: Preventive medicines: vaccination, prophylaxis of infectious diseases, disinfectants.
abstract: Immunizations belong to the most successful interventions in medicine. Like other drugs, vaccines undergo long periods of pre-clinical development, followed by careful clinical testing through study Phases I, II, and III before they receive licensure. A successful candidate vaccine will move on to be an investigational vaccine to undergo three phases of pre-licensure clinical trials in a stepwise fashion before it can be considered for approval, followed by an optional fourth phase of post-marketing assessment. The overall risk-benefit assessment of a candidate vaccine is very critical in making the licensure decision for regulatory authorities, supported by their scientific committees. It includes analyses of immunogenicity, efficacy, reactogenicity or tolerability, and safety of the vaccine. Public trust in vaccines is a key to the success of immunization programs worldwide. Maintaining this trust requires knowledge of the benefits and scientific understanding of real or perceived risks of immunizations. Under certain circumstances, pre- or post-exposure passive immunization can be achieved by administration of immunoglobulines. In terms of prevention of infectious diseases, disinfection can be applied to reduce the risk of transmission of pathogens from patient to patient, health-care workers to patients, patients to health-care workers, and objects or medical devices to patients.
authors: Universitäts-Kinderspital beider Basel, CH-4005 Basel, Switzerland. Ulrich.Heininger@ukbb.ch
authors: Ulrich
authors: U
authors: Heininger
mesh_terms: D000438:Alcohols / Q000627:therapeutic use; D000447:Aldehydes / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000379:methods; D003140:Communicable Disease Control / Q000379:methods*; D004202:Disinfectants / Q000627:therapeutic use*; D017277:Drug Approval / Q000331:legislation & jurisprudence / Q000379:methods; D004353:Drug Evaluation, Preclinical / Q000379:methods / Q000592:standards; D005060:Europe; D006801:Humans; D007116:Immunization, Passive / Q000379:methods; D016877:Oxidants / Q000627:therapeutic use; D010372:Pediatrics / Q000331:legislation & jurisprudence / Q000379:methods; D010636:Phenols / Q000627:therapeutic use; D011206:Povidone-Iodine / Q000627:therapeutic use; D011358:Product Surveillance, Postmarketing; D000644:Quaternary Ammonium Compounds / Q000627:therapeutic use; D014481:United States; D014611:Vaccination / Q000009:adverse effects / Q000379:methods*; D014612:Vaccines / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000438:Alcohols; D000447:Aldehydes; D004202:Disinfectants; D016877:Oxidants; D010636:Phenols; D000644:Quaternary Ammonium Compounds; D014612:Vaccines; D011206:Povidone-Iodine